PMID- 35499590
OWN - NLM
STAT- MEDLINE
DCOM- 20220608
LR  - 20240313
IS  - 1433-8726 (Electronic)
IS  - 0724-4983 (Print)
IS  - 0724-4983 (Linking)
VI  - 40
IP  - 6
DP  - 2022 Jun
TI  - Global experience and progress in GreenLight-XPS 180-Watt photoselective 
      vaporization of the prostate.
PG  - 1513-1522
LID - 10.1007/s00345-022-03997-2 [doi]
AB  - PURPOSE: To evaluate changes in global perioperative data of GreenLight-XPS 
      180-Watt photo-selective vaporization of the prostate (GL-XPS) of the Global 
      Greenlight Group (GGG) database. METHODS: 3441 men, who underwent GL-XPS for 
      symptomatic BPH between 2011 and 2019 at seven high volume international centers, 
      were included. Primary outcome measurements were operative time (OT; min), 
      effective laser time (LT; min of OT), as well as intraoperative and postoperative 
      adverse events (AEs), all analyzed by year of surgery (2011-2019) and prostate 
      volume (PV) group (< 80 ml vs. 80-150 ml vs. > 150 ml). RESULTS: The median age 
      was 70 years (interquartile range 64-77), the median PV was 64 ml (IQR 47-90). 
      The OT and LT slightly increased but stayed highly efficient all in all. Median 
      OT was 60 min (IQR 45-83) and LT was 33 min (IQR 23-46). Median energy use was 
      253 kJ (IQR 170-375) with an energy density of 3.94 kJ/ml (IQR 2.94-5.02). The 
      relative probability of perioperative AEs decreased by 17% each year (p < 0.001). 
      The relative probability of perioperative transfusion dropped significantly from 
      2% in 2011 to 0% in 2019 (p = 0.007). The early postoperative complications 
      (within 30 days after surgery) decreased significantly from 48.8% (n = 106) in 
      2011 to 24.7% (n = 20) in 2019 (p > 0.001). CONCLUSION: These findings from the 
      GGG demonstrate significant improvement secondary to growing experience with 
      GL-XPS between 2011 and 2019 in intraoperative AEs, including transfusions, and 
      postoperative AEs. While staying highly efficient in OT and LT of GL-XPS within a 
      9-year period of experience.
CI  - (c) 2022. The Author(s).
FAU - Lichy, Isabel
AU  - Lichy I
AUID- ORCID: 0000-0002-1680-3604
AD  - Department of Urology, Charite-University Medicine Berlin, Hindenburgdamm 30, 
      12203, Berlin, Germany. isabel-michaela.lichy@charite.de.
FAU - Law, Kyle
AU  - Law K
AD  - Department of Urology, University of Montreal Hospital Center (CHUM), Montreal, 
      Canada.
FAU - Tholomier, Come
AU  - Tholomier C
AD  - Division of Urology, Department of Surgery, McGill University, Montreal, QC, 
      Canada.
FAU - Nguyen, David-Dan
AU  - Nguyen DD
AD  - Faculty of Medicine and Health Sciences, McGill University, Montreal, Canada.
FAU - Sadri, Iman
AU  - Sadri I
AD  - Division of Urology, Department of Surgery, McGill University, Montreal, QC, 
      Canada.
FAU - Bouhadana, David
AU  - Bouhadana D
AD  - Faculty of Medicine and Health Sciences, McGill University, Montreal, Canada.
FAU - Couture, Felix
AU  - Couture F
AD  - Department of Urology, University of Montreal Hospital Center (CHUM), Montreal, 
      Canada.
FAU - Zakaria, Ahmed S
AU  - Zakaria AS
AD  - Division of Urology, Department of Surgery, Northern Ontario School of Medicine, 
      Thunder Bay, ON, Canada.
FAU - Bhojani, Naeem
AU  - Bhojani N
AD  - Department of Urology, University of Montreal Hospital Center (CHUM), Montreal, 
      Canada.
FAU - Zorn, Kevin C
AU  - Zorn KC
AD  - Department of Urology, University of Montreal Hospital Center (CHUM), Montreal, 
      Canada.
FAU - Bruyere, Franck
AU  - Bruyere F
AD  - Department of Oncology and Urology, Centre Hospitalier Universitaire de Tours, 
      Centre-Val de Loire, France.
FAU - Cindolo, Luca
AU  - Cindolo L
AD  - Department of Urology, Hesperia Hospital, Cure Group, Modena, Italy.
FAU - Ferrari, Giovanni
AU  - Ferrari G
AD  - Department of Urology, Hesperia Hospital, Cure Group, Modena, Italy.
FAU - Vasquez-Lastra, Carlos
AU  - Vasquez-Lastra C
AD  - Department of Urology, ABC Medical Center, Mexico City, Mexico.
FAU - Borelli-Bovo, Tiago J
AU  - Borelli-Bovo TJ
AD  - Borelli Urologia, Ribeirao Presto, Brazil.
FAU - Becher, Edgardo F
AU  - Becher EF
AD  - Centro de Urologia, CDU, Buenos Aires, Argentina.
FAU - Misrai, Vincent
AU  - Misrai V
AD  - Department of Urology, Clinique Pasteur, Toulouse, Midi-Pyrenees, France.
FAU - Elterman, Dean
AU  - Elterman D
AD  - Division of Urology, Dept. of Surgery, University Health Network, University of 
      Toronto, Toronto, ON, Canada.
FAU - Reimann, Maximilian
AU  - Reimann M
AD  - Department of Urology, Charite-University Medicine Berlin, Hindenburgdamm 30, 
      12203, Berlin, Germany.
FAU - Cash, Hannes
AU  - Cash H
AD  - Prouro, Urology Berlin, Berlin, Germany.
AD  - Department of Urology, University of Magdeburg, Magdeburg, Germany.
AD  - Department of Urology, University Hospital Magdeburg, Magdeburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20220502
PL  - Germany
TA  - World J Urol
JT  - World journal of urology
JID - 8307716
SB  - IM
MH  - Aged
MH  - Humans
MH  - *Laser Therapy/adverse effects
MH  - Male
MH  - Prostate/surgery
MH  - *Prostatic Hyperplasia/complications
MH  - Treatment Outcome
MH  - Volatilization
PMC - PMC9166849
OTO - NOTNLM
OT  - BPH
OT  - GL-XPS
OT  - Global Greenlight Group
OT  - Global experience
OT  - Greenlight
COIS- Hannes Cash, Kevin Zorn, Dean Elterman, Edgardo F. Becher, Giovanni Ferrari and 
      Luca Cindolo report receiving honoraria as consultant/proctor for Boston 
      Scientific. All other authors report no conflict of interest.
EDAT- 2022/05/03 06:00
MHDA- 2022/06/09 06:00
PMCR- 2022/05/02
CRDT- 2022/05/02 11:26
PHST- 2021/11/21 00:00 [received]
PHST- 2022/03/18 00:00 [accepted]
PHST- 2022/05/03 06:00 [pubmed]
PHST- 2022/06/09 06:00 [medline]
PHST- 2022/05/02 11:26 [entrez]
PHST- 2022/05/02 00:00 [pmc-release]
AID - 10.1007/s00345-022-03997-2 [pii]
AID - 3997 [pii]
AID - 10.1007/s00345-022-03997-2 [doi]
PST - ppublish
SO  - World J Urol. 2022 Jun;40(6):1513-1522. doi: 10.1007/s00345-022-03997-2. Epub 
      2022 May 2.